Triptorelin

Triptorelin is a synthetic ten-amino-acid peptide (decapeptide) that acts as a stronger, longer-lasting version of the brain's gonadotropin-releasing hormone (GnRH). GnRH is the master signal that tells the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive testosterone and estrogen production ¹.

In the body, Triptorelin first causes a brief burst of LH and FSH, called a flare. With continued exposure, the pituitary stops responding, and testosterone or estradiol falls to very low levels ². This dual action underlies two different clinical uses: a single small dose can trigger ovulation in fertility treatment, while a depot injection every few weeks or months can suppress the reproductive axis ⁶.

The compound is available as acetate and pamoate (embonate) salts in slow-release microsphere depots for intramuscular injection, and as low-dose solutions for subcutaneous use in diagnostic testing and assisted reproduction ⁸. A dedicated delivery system was approved in the United States in 2008 for advanced prostate cancer and central precocious puberty ⁷.

Studied indication	Evidence base
Advanced prostate cancer	Human RCTs 2
Central precocious puberty	Human RCTs and large cohorts 8
Endometriosis	Human RCTs and controlled studies 5
Uterine fibroids	Human RCTs 23
Premenopausal hormone-receptor-positive breast cancer	Phase III RCT, 10-year follow-up 10
Ovulation trigger and IVF downregulation	Human RCTs 17
Diagnostic stimulation testing	Human RCT and observational studies 15

Triptorelin works at the gonadotrophs, the cells in the anterior pituitary that produce LH and FSH. It binds to the GnRH receptor (GnRHR), a receptor coupled to Gαq/11 proteins, and initially activates the same pathway as natural GnRH: phospholipase C, a rise in intracellular calcium, and release of stored LH and FSH ¹. In a diagnostic test, a 100 mcg dose produces an LH peak within 30 to 120 minutes ¹⁵.

With persistent receptor occupancy, the signal inverts. Receptors are pulled inside the cell and their gene expression falls, so the pituitary becomes desensitized to further stimulation ¹. LH and FSH output then drops, and the ovaries or testes receive almost no drive. In prostate cancer, the result is castrate-level testosterone: 91.2% of men reached the threshold by day 29 and 97.7% by day 57 on a 3.75 mg monthly depot ². In central precocious puberty, 92% of children achieved profound LH suppression within three months on an 11.25 mg depot ⁸.

Triptorelin also binds GnRH receptors found on some breast, ovarian, and endometrial cancer cells. In cell studies it blocked estrogen-driven growth signals through the MAPK/SRE pathway rather than the classical estrogen response element ³. One animal study found that continuous pubertal blockade also shifted hypothalamic metabolic gene expression in a sex-specific pattern, a reminder that GnRH receptor activation affects more than the gonads ¹.

Across indications, the documented clinical effects track the same biologic switch: a brief surge followed by lasting hormone suppression.

• Prostate cancer: pooled phase III data of 592 men showed 96% reached a testosterone nadir below 0.35 nmol/L (10 ng/dL), and a lower nadir was associated with significantly better overall survival and, in sensitivity analyses, better disease-specific survival ². In a head-to-head trial, suppression was slightly slower at day 29 than leuprolide but equivalent from day 57 onward ⁶.
• Central precocious puberty: the 6-monthly 22.5 mg depot suppressed LH in 100% of girls through 36 months, estradiol was suppressed at every measurement, breast development arrested in 51% or regressed in 32.4%, and predicted adult height increased by 5.4 cm on average ¹¹. A UK cohort found 24-weekly dosing equivalent to 12-weekly for endocrine control and growth ¹².
• Assisted reproduction: a single Triptorelin trigger after GnRH-antagonist cycles is a landmark strategy for reducing ovarian hyperstimulation syndrome (OHSS) ¹⁷. In women with diminished ovarian reserve, dual trigger with 0.2 mg Triptorelin plus HCG increased mature oocytes, good-quality embryos, and implantation versus HCG alone ¹⁸. In good-prognosis fertility preservation, dual trigger added no benefit over Triptorelin alone ¹⁹.
• Gynecology: three months of Triptorelin plus mifepristone reduced menstrual flow and fibroid volume and improved uterine artery blood flow in fibroids ²³. A single case documented resolution of pulmonary endometriosis nodules after six months of depot treatment ²⁴.
• Rodent development: in pubertal rats, Triptorelin caused sex-specific metabolic changes: females gained more weight with delayed hyperphagia, while males gained less and moved more ¹. Testicular changes were reversible and focal, with sperm production maintained ²⁵.

The evidence is strongest for FDA-approved indications. Effects in assisted reproduction are context-dependent and vary by patient population ¹⁸.

Triptorelin dosing is generally fixed for adults and children and not adjusted by body weight, but some pediatric protocols use weight-based dosing (e.g., 100 mcg/kg IM every 4 weeks). Population pharmacokinetic modeling found higher exposure in lighter children, but because LH suppression reaches a plateau, the same 3.75 mg dose is used across weights ¹⁴.

Common regimens reported in the literature:

Indication	Regimen	Notes
Prostate cancer	3.75 mg IM every 28 days; 11.25 mg every 12 weeks; 22.5 mg every 24 weeks	Continue until disease progression 2
Central precocious puberty	3.75 mg IM every 4 weeks, or 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks	Intervals can be individualized to 3 to 5 weeks on monthly dosing based on suppression 8
Endometriosis and fibroids	3.0 to 3.75 mg depot monthly	Typical duration 3 to 6 months 23
IVF final oocyte maturation trigger	0.1 to 0.3 mg SC as a single dose, about 36 hours before retrieval	Dual trigger adds HCG in selected poor responders 17
IVF long-protocol downregulation	depot 1.25 mg once	One-third dose prevented LH surge comparably to 1.87 mg with lower cost 22
Diagnostic stimulation test	100 mcg SC or IM once	LH sampled at 30 to 120 minutes; a peak LH at or above 6 IU/L supports CPP 15

When used as a trigger, timing is precise relative to follicle size and retrieval, generally 36 hours before oocyte retrieval in trial protocols ¹⁷. Depot injections have no meal or time-of-day restrictions, and both intramuscular and subcutaneous routes are equivalent for diagnostic testing ³².

Clinical Triptorelin is supplied as a depot microsphere kit, not a bulk vial that the user dilutes to a chosen concentration. The vials are paired with a fixed-volume diluent; the goal is to suspend the microspheres, not to create a customizable solution. Manufacturer guidance is to swirl gently rather than shake, because physical stress can break the polymer microspheres and change the release profile ⁵⁷. Once suspended, the mixture is not bacteriostatic, so it is injected immediately and never stored.

Low-dose diagnostic and trigger preparations are simple aqueous solutions given subcutaneously or intramuscularly; these include the 100 mcg stimulation test and the 0.2 to 0.3 mg IVF trigger ¹⁵.

For research-grade lyophilized triptorelin, community protocols follow standard peptide handling: bacteriostatic water as diluent, gentle mixing, refrigerated storage, and a limited use window after mixing. The interactive calculator in this section handles the dilution arithmetic for that research context. Unopened commercial depot kits should be stored at 2 to 8°C and protected from light ⁵⁷.

Triptorelin has no documented cytochrome P450 metabolic interactions, because it is a peptide degraded by tissue peptidases. Interactions are mostly pharmacodynamic, meaning they involve what other drugs do to the same hormone axis ⁵⁴.

Important documented combinations:

• Antiandrogens: cyproterone acetate, bicalutamide, or flutamide are used around the first depot to blunt the testosterone flare before suppression takes hold in prostate cancer ⁵⁵.
• Aromatase inhibitors and tamoxifen: in premenopausal hormone-receptor-positive breast cancer, ovarian suppression with Triptorelin plus exemestane or letrozole produces deeper estrogen suppression than Triptorelin alone ¹⁰.
• Mifepristone: a three-month combination with Triptorelin is studied for uterine fibroids; adding Huayu Xiaozheng decoction further improved outcomes in one trial ²³.
• HCG: dual trigger with Triptorelin plus HCG improved oocyte yield in women with diminished ovarian reserve but added no benefit in good-prognosis fertility preservation ¹⁸.
• GnRH antagonists: in PCOS patients at high OHSS risk, cetrorelix-based protocols are preferred over Triptorelin-based downregulation ²¹.
• Ciclosporin: one case report documented generalized hypertrichosis despite concurrent Triptorelin-driven androgen suppression, showing testosterone blockade does not prevent this effect ²⁹.
• Heparin: in cell work, Triptorelin plus heparin reduced the conversion of estrone sulfate to estradiol in MCF-7 cells, but this remains theoretical in humans ³⁵.

No formal drug-interaction trials exist for many co-exposures; where evidence is absent, the effects are inferred from mechanism.

Triptorelin is not cycled in the way some peptide protocols are. For suppression indications, continuous depot coverage is required; a gap allows the axis to start recovering ¹.

By indication:

• IVF trigger: one dose per cycle only, with repetition only in a later stimulated cycle. There is no taper and no washout needed ¹⁷.
• Uterine fibroids and endometriosis: courses are time-limited, typically 3 to 6 months, to control symptoms while limiting bone loss from prolonged estrogen suppression ²³.
• Central precocious puberty: treatment lasts until bone age reaches the target in girls, with the 24-week depot equivalent to 12-week dosing for suppression across 36 months ¹¹.
• Prostate cancer: androgen deprivation is continuous or intermittent; each re-start is supported by antiandrogen flare protection ².

Desensitization is not a failure of the drug that requires cycling; it is the intended therapeutic mechanism ¹. Animal data suggest testicular changes from exposure are reversible, with sperm production maintained ²⁵. In female rats, some hypothalamic metabolic changes were observed after 28 days of treatment, a caution about broader neuroendocrine effects ¹.

Because Triptorelin sets the background hormone state, most studied combinations pair it with an agent that either protects against flare, adds anti-tumor effect, or supports fertility and growth.

• With growth hormone (rhGH): in short-stature central precocious puberty, triptorelin plus growth hormone improved predicted adult height by about 4 cm over two years in one series ³⁹.
• With HCG: dual trigger in poor-responder IVF increased mature oocyte and embryo yield compared with HCG alone ¹⁸. In good-prognosis patients, the combination did not outperform Triptorelin alone ¹⁹.
• With aromatase inhibitors or tamoxifen: in premenopausal breast cancer, the HOBOE 10-year update supports triptorelin plus letrozole with or without zoledronic acid ¹⁰; exemestane plus triptorelin suppressed estradiol further than triptorelin alone ⁵⁴.
• With mifepristone and a herbal decoction: for fibroids, triptorelin plus mifepristone and Huayu Xiaozheng decoction reduced fibroid volume and adverse reactions in an RCT ²³.
• With HMG/FSH: during controlled ovarian stimulation, triptorelin trigger or downregulation is combined with gonadotropins; no adverse interaction is reported across the trigger literature ¹⁸.

Many non-approved combinations exist only as community practice. The published evidence for Triptorelin stacks is strongest where a trial explicitly tested the combination.

Triptorelin is an FDA-approved prescription injectable in the United States, with a delivery system approved in 2008 for central precocious puberty and advanced prostate cancer ⁷. It is not a controlled substance, but it is Rx-only and distributed through specialty pharmacy.

Other regions have long-standing authorizations: Australia's PBS has listed triptorelin since at least 1996 among the LHRH agonists used for androgen deprivation ⁹. The United Kingdom embedded the 6-monthly formulation in NHS prostate cancer pathways and documented reduced patient-hospital interactions in the DESERVE program ⁶¹. France's TALISMAN study reflects real-world oncology use ⁶², and China has developed domestic microsphere formulations supported by population pharmacokinetic work ¹⁴.

Use as puberty suppression for gender-dysphoric adolescents is the main legal flashpoint. A 2025 comparative legal analysis argues for protected access, while some US states enacted restrictions on gender-affirming care for minors between 2023 and 2025 ⁵⁹. The published literature does not enumerate specific statutes, so local verification is needed.

In sport, GnRH agonists are prohibited under WADA rules. Doping-control labs maintain validated liquid chromatography-mass spectrometry methods to detect Triptorelin and its metabolites in urine ³⁰. The literature notes that athletes prescribed Triptorelin normally need therapeutic use exemption documentation.

Safety follows the expected pattern of deep hormone suppression, with a few drug-specific injection issues.

Common: hot flushes, sweats, reduced libido, menstrual irregularity, and erectile dysfunction reflect low sex-steroid levels ². The first depot can cause a temporary flare of LH, FSH, and testosterone; in advanced prostate cancer this can worsen bone pain or urinary obstruction, so antiandrogen cover is standard at initiation ⁵⁵. In children, height velocity slows to about 5.5, 4.6, and then 3.8 cm per year over years one to three ¹¹.

Injection site: sterile abscesses occurred in about 0.7% of pediatric depot injections in one series ²⁷. First-dose anaphylaxis is rare and may be caused by the excipient polysorbate 80 rather than the peptide itself ²⁸.

Development and behavior: girls treated for central precocious puberty matched controls on cognitive and psychosocial testing, but showed higher emotional reactivity on one task and a lower resting heart rate that correlated with treatment duration ²⁶. Hair loss has also been reported in children on long-acting Triptorelin ⁵¹.

Bone and metabolic: prolonged suppression reduces bone mineral density; tibolone add-back has been studied to reduce hypoestrogenic effects in benign gynecologic use ⁴⁹. In pubertal rats, treatment shifted body weight and hypothalamic metabolic genes in opposite directions in females and males ¹. Animal data also show reversible, focal, partial testicular atrophy with maintained sperm production ²⁵.

Rare signals: a woman with a FSH-secreting gonadotroph adenoma developed paradoxical ovarian hyperstimulation after Triptorelin exposure, resolved by surgery ³⁶. Elevated sister chromatid exchange frequency was reported in one older IVF study without clinical sequelae ⁴⁸.